title: Intravenous busulfan: a guide to its use as conditioning treatment before transplantation of haematopoietic progenitor cells.
abstract: With intravenous administration of busulfan (Busilvex®), the therapeutic range of the drug is achieved in more paediatric patients than after oral busulfan administration. In clinical trials in paediatric and adult patients, intravenous busulfan-based preconditioning treatment regimen prior to haematopoietic progenitor cell transplantation (HPCT) provided high rates of engraftment, low transplant-related mortality rates and good overall survival and progression-free survival outcomes. Intravenous busulfan was considered to have an acceptable tolerability profile.
authors.affiliation: Adis, Auckland, New Zealand. demail@springer.com
authors.forename: Lesley J
authors.initials: LJ
authors.lastname: Scott
authors.forename: Sheridan M
authors.initials: SM
authors.lastname: Hoy
authors.forename: Katherine A
authors.initials: KA
authors.lastname: Lyseng-Williamson
mesh_terms: D000293:Adolescent; D000328:Adult; D002066:Busulfan / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous; D017410:Practice Guidelines as Topic; D019172:Transplantation Conditioning
chemical_list: D002066:Busulfan